Vistagen Therapeutics Dirección
Dirección controles de criterios 1/4
El CEO de Vistagen Therapeutics es Shawn Singh , nombrado en Aug 2009, tiene una permanencia de 15.25 años. compensación anual total es $947.92K, compuesta por 65.7% salario y 34.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.11% de las acciones de la empresa, por valor de $80.92K. La antigüedad media del equipo directivo y de la junta directiva es de 1.7 años y 8.7 años, respectivamente.
Información clave
Shawn Singh
Chief Executive Officer (CEO)
US$947.9k
Compensación total
| Porcentaje del salario del CEO | 65.7% |
| Permanencia del CEO | 15.3yrs |
| Participación del CEO | 0.1% |
| Permanencia media de la dirección | 1.7yrs |
| Promedio de permanencia en la Junta Directiva | 8.7yrs |
Actualizaciones recientes de la dirección
Recent updates
We're Hopeful That Vistagen Therapeutics (NASDAQ:VTGN) Will Use Its Cash Wisely
Nov 15
VistaGen to proceed with phase 3 anxiety nasal spray trial following interim analysis
Sep 08VistaGen drops 80% as late-stage study for anxiety therapy fails
Jul 22Here's Why We're Not Too Worried About VistaGen Therapeutics' (NASDAQ:VTGN) Cash Burn Situation
Apr 10VistaGen Therapeutics added to Russell 2000 Index
Jun 16VistaGen Therapeutics (NASDAQ:VTGN) Is In A Strong Position To Grow Its Business
Jun 07VistaGen initiates late-stage trial of PH94B in social anxiety disorder
May 26VistaGen names new chief commercial officer
May 04How Does VistaGen Therapeutics' (NASDAQ:VTGN) CEO Salary Compare to Peers?
Feb 16
VistaGen Therapeutics regains Nasdaq listing compliance
Jan 06VistaGen Therapeutics slumps in after hours trade on underwritten public offering
Dec 17Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$40m |
| Jun 30 2024 | n/a | n/a | -US$33m |
| Mar 31 2024 | US$948k | US$623k | -US$29m |
| Dec 31 2023 | n/a | n/a | -US$32m |
| Sep 30 2023 | n/a | n/a | -US$35m |
| Jun 30 2023 | n/a | n/a | -US$46m |
| Mar 31 2023 | US$600k | US$600k | -US$59m |
| Dec 31 2022 | n/a | n/a | -US$64m |
| Sep 30 2022 | n/a | n/a | -US$65m |
| Jun 30 2022 | n/a | n/a | -US$60m |
| Mar 31 2022 | US$1m | US$563k | -US$49m |
| Dec 31 2021 | n/a | n/a | -US$62m |
| Sep 30 2021 | n/a | n/a | -US$56m |
| Jun 30 2021 | n/a | n/a | -US$47m |
| Mar 31 2021 | US$1m | US$511k | -US$42m |
| Dec 31 2020 | n/a | n/a | -US$16m |
| Sep 30 2020 | n/a | n/a | -US$17m |
| Jun 30 2020 | n/a | n/a | -US$19m |
| Mar 31 2020 | US$934k | US$498k | -US$22m |
| Dec 31 2019 | n/a | n/a | -US$24m |
| Sep 30 2019 | n/a | n/a | -US$26m |
| Jun 30 2019 | n/a | n/a | -US$28m |
| Mar 31 2019 | US$951k | US$466k | -US$26m |
| Dec 31 2018 | n/a | n/a | -US$24m |
| Sep 30 2018 | n/a | n/a | -US$20m |
| Jun 30 2018 | n/a | n/a | -US$18m |
| Mar 31 2018 | US$1m | US$425k | -US$16m |
Compensación vs. Mercado: La compensación total de Shawn($USD947.92K) está por encima de la media de empresas de tamaño similar en el mercado US ($USD649.07K).
Compensación vs. Ingresos: La compensación de Shawn ha aumentado mientras la empresa no es rentable.
CEO
Shawn Singh (61 yo)
15.3yrs
Permanencia
US$947,917
Compensación
Mr. Shawn K. Singh, J.D. has been the Chief Executive Officer at VistaGen Therapeutics, Inc., since August 20, 2009. Mr. Singh serves as the Chief Business Officer and General Counsel at Cato Research Ltd....
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 15.3yrs | US$947.92k | 0.11% $ 80.9k | |
| VP & Chief Financial Officer | 1.3yrs | US$434.19k | 0.013% $ 9.3k | |
| Chief Operating Officer | 2yrs | US$568.44k | 0.0096% $ 6.9k | |
| Chief Corporate Development Officer & General Counsel | 2.5yrs | US$675.00k | 0.059% $ 42.6k | |
| Senior Vice President of Investor Relations | 1.6yrs | US$479.99k | sin datos | |
| Senior Vice President of Human Resources | no data | sin datos | sin datos | |
| Senior Vice President of Development Operations | no data | sin datos | sin datos | |
| Senior VP and Head of Chemistry | 3.8yrs | sin datos | sin datos | |
| Senior Vice President of Corporate Strategy & Capital Markets | 1.6yrs | sin datos | sin datos | |
| Senior Vice President of Global Regulatory Affairs & Pharmacovigilance | 1.3yrs | sin datos | sin datos | |
| Senior Vice President of Translational Neuroscience | less than a year | sin datos | sin datos | |
| VP, Associate General Counsel & Secretary | 1.8yrs | sin datos | sin datos |
1.7yrs
Permanencia media
56yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de VTGN no se considera experimentado ( 1.7 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 13.8yrs | US$947.92k | 0.11% $ 80.9k | |
| Independent Director | 24.8yrs | US$129.37k | 0.0067% $ 4.8k | |
| Independent Director | 8.7yrs | US$128.12k | 0.048% $ 34.4k | |
| Chairman of Scientific Advisory Board | 1.9yrs | sin datos | sin datos | |
| Member of Clinical & Regulatory Advisory Board | 8.7yrs | sin datos | sin datos | |
| Member of Clinical & Regulatory Advisory Board | 9.1yrs | sin datos | sin datos | |
| Member of CNS Clinical and Regulatory Advisory Board | 6.1yrs | sin datos | sin datos | |
| Independent Chair of the Board | 3.3yrs | US$185.62k | 0% $ 0 | |
| Member of Clinical & Regulatory Advisory Board | 7.3yrs | sin datos | sin datos | |
| Member of Clinical & Regulatory Advisory Board | 9.8yrs | sin datos | sin datos | |
| Independent Director | 3.3yrs | US$128.12k | 0% $ 0 | |
| Member of Clinical & Regulatory Advisory Board | 8.7yrs | sin datos | sin datos |
8.7yrs
Permanencia media
64yo
Promedio de edad
Junta con experiencia: La junta directiva de VTGN se considera experimentada (8.7 años de antigüedad promedio).